GeneReach Biotechnology (4171) — Capital Reinvestment Ratio
Latest as of December 2025:
0.38x
GeneReach Biotechnology (4171) has a Capital Reinvestment Ratio of 0.38x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$12.05 Million) in capital expenditures (NT$4.58 Million). See GeneReach Biotechnology (4171) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.38x
Capex / Operating Cash Flow
Operating Cash Flow
NT$12.05 Million
TWD
Capital Expenditures
NT$4.58 Million
TWD
Data as of
Dec 2025
Most recent filing
GeneReach Biotechnology Capital Reinvestment Ratio (2018–2022)
This chart tracks GeneReach Biotechnology's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for GeneReach Biotechnology (2018–2022)
Year-by-year Capital Reinvestment Ratio for GeneReach Biotechnology from 2018 to 2022. For live market cap and broader valuation context, see GeneReach Biotechnology stock valuation.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.13x | NT$357.63 Million | NT$44.90 Million | ▲ +177.5% |
| 2021 | 0.05x | NT$348.99 Million | NT$15.79 Million | ▼ -88.2% |
| 2020 | 0.38x | NT$169.82 Million | NT$64.87 Million | ▼ -4.9% |
| 2018 | 0.40x | NT$5.74 Million | NT$2.31 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow